MicroRNA-409-3p Represses Glioma Cell Invasion and Proliferation by Targeting High-Mobility Group Nucleosome-Binding Domain 5

Overview

Journal Oncol Res

Specialty Oncology

Date 2017 Jan 22

PMID 28109076

Citations 9

Authors

Yidong Cao

Liang Zhang

Minghao Wei

Xue Jiang

Dong Jia

Affiliations

Soon will be listed here.

Abstract

Emerging evidence has suggested that aberrantly expressed microRNAs (miRNAs) are associated with glioma development and progression. The aberrant expression of miR-409-3p has been reported in several human cancers. However, little is known about the function of miR-409-3p in gliomas. The aim of this study was to investigate the specific role and molecular mechanism of miR-409-3p in gliomas. In the present study, we found that miR-409-3p was downregulated in glioma tissue and cell lines. Overexpression of miR-409-3p inhibited glioma cell invasion and proliferation, whereas suppression of miR-409-3p promoted glioma cell invasion and proliferation. High-mobility group nucleosome-binding domain 5 (HMGN5), a well-known oncogene in gliomas, was identified as a functional target of miR-409-3p using bioinformatics, dual-luciferase reporter assay, real-time quantitative polymerase chain reaction, and Western blot analysis. Furthermore, miR-409-3p was found to regulate the expression of matrix metalloproteinase 2 and cyclin D1. Restoration of HMGN5 expression significantly reversed the inhibitory effects of miR-409-3p overexpression on glioma cell invasion and proliferation. Taken together, our results suggest that miR-409-3p inhibits glioma cell invasion and proliferation by targeting HMGN5, representing a potential therapeutic target for glioma.

Citing Articles

Long noncoding RNA SNHG4 promotes glioma progression via regulating miR-367-3p/MYO1B axis in zebrafish xenografts.

Zhang Y, Wang Y, Yang Y, Sun C Hum Cell. 2025; 38(2):53.

PMID: 39951205 PMC: 11828807. DOI: 10.1007/s13577-025-01183-1.

Investigating the molecular mechanisms of microRNA‑409‑3p in tumor progression: Towards targeted therapeutics (Review).

Xie W, Wang Z, Wang J, Wang X, Guan H Int J Oncol. 2024; 65(1).

PMID: 38757364 PMC: 11155714. DOI: 10.3892/ijo.2024.5655.

MicroRNA-409: Molecular functions and clinical applications in cancer.

Rajabloo Y, Latifi H, Akhlaghipour I, Taghehchian N, Moghbeli M Biochem Biophys Rep. 2024; 38:101728.

PMID: 38737729 PMC: 11087923. DOI: 10.1016/j.bbrep.2024.101728.

MicroRNA-409-5p inhibits cell proliferation, and induces G/M phase arrest and apoptosis by targeting DLGAP5 in ovarian cancer cells.

Li W, Lin J, Huang J, Chen Z, Sheng Q, Yang F Oncol Lett. 2022; 24(2):261.

PMID: 35765271 PMC: 9219020. DOI: 10.3892/ol.2022.13381.

Hsa_circ_0000418 promotes the progression of glioma by regulating microRNA-409-3p / pyruvate dehydrogenase kinase 1 axis.

Ma Z, Chen Z, Zhou Y, Li Y, Li S, Wang H Bioengineered. 2022; 13(3):7541-7552.

PMID: 35264067 PMC: 8974101. DOI: 10.1080/21655979.2022.2049027.

References

Gan Y, Tan J, Yang J, Zhou Y, Dai Y, He L . Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo. Med Oncol. 2015; 32(4):136. DOI: 10.1007/s12032-015-0594-y. View

Jiang N, Zhou L, Zhang X . Downregulation of the nucleosome-binding protein 1 (NSBP1) gene can inhibit the in vitro and in vivo proliferation of prostate cancer cells. Asian J Androl. 2010; 12(5):709-17. PMC: 3739312. DOI: 10.1038/aja.2010.39. View

Ji S, Yao L, Zhang X, Li X, Zhou L . Knockdown of the nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal cell carcinoma cells in vitro and in vivo. J Exp Clin Cancer Res. 2012; 31:22. PMC: 3325891. DOI: 10.1186/1756-9966-31-22. View

Liu M, Xu A, Yuan X, Zhang Q, Fang T, Wang W . Downregulation of microRNA-409-3p promotes aggressiveness and metastasis in colorectal cancer: an indication for personalized medicine. J Transl Med. 2015; 13:195. PMC: 4472171. DOI: 10.1186/s12967-015-0533-x. View

Khalil S, Fabbri E, Santangelo A, Bezzerri V, Cantu C, Di Gennaro G . miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma. Oncotarget. 2016; 7(19):28195-206. PMC: 5053720. DOI: 10.18632/oncotarget.8618. View

Yang C, Gao R, Wang J, Yuan W, Wang C, Zhou X . High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy. Tumour Biol. 2014; 35(7):6357-63. DOI: 10.1007/s13277-014-1833-0. View

Winter J, Jung S, Keller S, Gregory R, Diederichs S . Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009; 11(3):228-34. DOI: 10.1038/ncb0309-228. View

Zhou X, Yuan B, Yuan W, Wang C, Gao R, Wang J . The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma. Tumour Biol. 2014; 35(7):6539-47. DOI: 10.1007/s13277-014-1825-0. View

Zhou S, Shen J, Lin S, Liu X, Xu M, Shi L . Downregulated expression of DIXDC1 in hepatocellular carcinoma and its correlation with prognosis. Tumour Biol. 2016; 37(10):13607-13616. DOI: 10.1007/s13277-016-5213-9. View

10.

Hummel R, Maurer J, Haier J . MicroRNAs in brain tumors : a new diagnostic and therapeutic perspective?. Mol Neurobiol. 2011; 44(3):223-34. DOI: 10.1007/s12035-011-8197-x. View

11.

Josson S, Gururajan M, Hu P, Shao C, Chu G, Zhau H . miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res. 2014; 20(17):4636-46. PMC: 4155061. DOI: 10.1158/1078-0432.CCR-14-0305. View

12.

Ganju A, Khan S, Hafeez B, Behrman S, Yallapu M, Chauhan S . miRNA nanotherapeutics for cancer. Drug Discov Today. 2016; 22(2):424-432. PMC: 5309208. DOI: 10.1016/j.drudis.2016.10.014. View

13.

King L, Francomano C . Characterization of a human gene encoding nucleosomal binding protein NSBP1. Genomics. 2001; 71(2):163-73. DOI: 10.1006/geno.2000.6443. View

14.

Shirakawa H, Landsman D, Postnikov Y, Bustin M . NBP-45, a novel nucleosomal binding protein with a tissue-specific and developmentally regulated expression. J Biol Chem. 2000; 275(9):6368-74. DOI: 10.1074/jbc.275.9.6368. View

15.

Manikandan J, Aarthi J, Kumar S, Pushparaj P . Oncomirs: the potential role of non-coding microRNAs in understanding cancer. Bioinformation. 2008; 2(8):330-4. PMC: 2478731. DOI: 10.6026/97320630002330. View

16.

Li C, Nie H, Wang M, Su L, Li J, Yu B . MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer. Cancer Lett. 2012; 320(2):189-97. DOI: 10.1016/j.canlet.2012.02.030. View

17.

Qu J, Yan R, Chen J, Xu T, Zhou J, Wang M . HMGN5: a potential oncogene in gliomas. J Neurooncol. 2011; 104(3):729-36. DOI: 10.1007/s11060-011-0558-9. View

18.

Li J, Yuan J, Yuan X, Zhao J, Zhang Z, Weng L . MicroRNA-200b inhibits the growth and metastasis of glioma cells via targeting ZEB2. Int J Oncol. 2015; 48(2):541-50. DOI: 10.3892/ijo.2015.3267. View

19.

Nohata N, Goto Y, Gutkind J . Onco-GPCR signaling and dysregulated expression of microRNAs in human cancer. J Hum Genet. 2016; 62(1):87-96. DOI: 10.1038/jhg.2016.124. View

20.

Zhang X, Guo Z, Ji S, Zhang M, Jiang N, Li X . Small interfering RNA targeting HMGN5 induces apoptosis via modulation of a mitochondrial pathway and Bcl-2 family proteins in prostate cancer cells. Asian J Androl. 2012; 14(3):487-92. PMC: 3720167. DOI: 10.1038/aja.2012.18. View